力生制药(002393) - 2025 Q3 - 季度财报

Financial Performance - Q3 2025 revenue was CNY 275,772,357.58, a decrease of 1.20% year-over-year[5] - Net profit attributable to shareholders was CNY 27,816,377.14, down 58.42% compared to the same period last year[5] - The net profit excluding non-recurring gains and losses increased by 215.67% to CNY 22,500,091.96 for the quarter[5] - Total operating revenue for the current period is ¥1,007,280,440.26, a decrease of 1.5% from ¥1,023,773,647.92 in the previous period[19] - Total operating costs decreased to ¥871,042,976.72, down 3.6% from ¥903,119,117.83[19] - Operating profit increased significantly to ¥446,001,766.23, compared to ¥201,408,039.28 in the previous period, representing a growth of 121.5%[20] - Net profit for the current period reached ¥374,284,895.92, up 122.3% from ¥168,334,446.76 in the previous period[20] - Basic and diluted earnings per share improved to ¥1.44, compared to ¥0.66 in the previous period[21] Assets and Liabilities - Total assets at the end of the reporting period were CNY 5,921,182,710.88, reflecting a 2.35% increase from the end of the previous year[5] - As of September 30, 2025, the company's total assets amounted to ¥5,921,182,710.88, an increase from ¥5,785,511,812.28 at the beginning of the period[16] - Total current liabilities decreased to ¥680,470,444.16 from ¥746,527,866.55, a reduction of about 8.8%[16] - The company's total equity increased to ¥5,003,333,340.77 from ¥4,799,975,192.40, representing a growth of approximately 4.2%[17] - The company's inventory decreased to ¥209,740,616.35 from ¥224,365,964.79, a decline of about 6.5%[15] - The company's accounts receivable increased to ¥258,102,265.86 from ¥207,964,785.31, an increase of approximately 24%[15] Cash Flow and Investments - Cash flow from operating activities for the year-to-date was CNY 124,819,596.56, an increase of 35.98%[5] - Cash flow from operating activities generated a net amount of ¥124,819,596.56, an increase from ¥91,795,856.55 in the previous period[21] - Cash flow from investment activities resulted in a net outflow of ¥350,088,014.01, slightly improved from a net outflow of ¥360,312,732.89 in the previous period[22] - The company's cash and cash equivalents decreased to ¥1,227,839,683.33 from ¥1,638,999,235.40, reflecting a decline of approximately 25.1%[15] - Cash and cash equivalents at the end of the period totaled ¥1,227,242,885.76, down from ¥1,537,434,495.00 at the end of the previous period[22] - Investment income for the period increased by 316.03% year-over-year, primarily due to dividends declared by Tianjin Tasly Biological Pharmaceutical Group[9] - The company reported a significant increase in investment income to ¥319,543,582.30, compared to ¥76,807,083.51 in the previous period[20] Borrowings and Equity - Short-term borrowings decreased by 37.17% compared to the beginning of the year, indicating reduced loan activity[9] - The company's short-term borrowings decreased to ¥25,000,000.00 from ¥39,790,877.05, a decline of about 37.4%[16] - The company's long-term investments in other equity instruments remained stable at ¥1,294,988,767.84, showing minimal change from ¥1,295,159,677.96[15] - The company's retained earnings increased to ¥1,736,370,355.18 from ¥1,459,524,542.12, reflecting a growth of approximately 18.9%[17] Share Repurchase - The company repurchased 1,439,980 shares as of September 30, 2025[12] Audit Status - The company has not undergone an audit for the third quarter financial report[23]